maklogo
Market Research Report

Global Oncology Molecular Diagnostic Market Insights, Size, and Forecast By Sample Type (Blood, Tissue, Bone Marrow, Urine, Saliva), By Test Type (Polymerase Chain Reaction, Next Generation Sequencing, In Situ Hybridization, Mass Spectrometry, Fluorescent In Situ Hybridization), By End Use (Hospitals, Diagnostic Laboratories, Research Institutions, Homecare), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Hematological Malignancies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:25411
Published Date:Jan 2026
No. of Pages:245
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Oncology Molecular Diagnostic Market is projected to grow from USD 16.8 Billion in 2025 to USD 52.2 Billion by 2035, reflecting a compound annual growth rate of 11.4% from 2026 through 2035. This robust expansion underscores the critical role of molecular diagnostics in modern oncology, encompassing tests that identify specific genetic mutations, gene expressions, or other biomarkers associated with cancer for improved diagnosis, prognosis, and treatment selection. The market is propelled by several key drivers, including the increasing global incidence of various cancer types, the growing demand for personalized medicine approaches in oncology, and significant advancements in genomic sequencing technologies. Furthermore, rising awareness among healthcare professionals and patients regarding the benefits of early and precise cancer detection, coupled with the expanding applications of companion diagnostics, are substantially contributing to market growth. The increasing number of research and development activities focused on discovering novel biomarkers and developing innovative diagnostic platforms also plays a pivotal role.

Global Oncology Molecular Diagnostic Market Value (USD Billion) Analysis, 2025-2035

maklogo
11.4%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Important trends shaping the market include the rapid adoption of next-generation sequencing NGS for comprehensive genomic profiling, the emergence of liquid biopsies for non-invasive cancer detection and monitoring, and the integration of artificial intelligence and machine learning into diagnostic workflows for enhanced data analysis and interpretation. The leading segment, Polymerase Chain Reaction, continues to hold a substantial market share due to its established reliability, cost-effectiveness, and broad applicability across various cancer types and diagnostic stages. Despite the positive outlook, the market faces certain restraints, such as the high cost associated with advanced molecular diagnostic tests and the complex regulatory frameworks for test approval and reimbursement in different regions. Additionally, a lack of skilled professionals to interpret complex genomic data and the ethical concerns surrounding genetic testing can impede market penetration. However, the market presents significant opportunities through the development of multiplex assays capable of detecting multiple biomarkers simultaneously, the expansion into emerging markets with unmet medical needs, and the integration of molecular diagnostics into routine clinical practice for early screening and recurrence monitoring.

North America stands as the dominant region in the global oncology molecular diagnostic market, primarily driven by a well-established healthcare infrastructure, high healthcare expenditure, significant research and development investments, and the early adoption of advanced diagnostic technologies. The presence of key market players and a favorable reimbursement landscape also contribute to its leading position. Conversely, Asia Pacific is projected to be the fastest growing region, fueled by rising cancer prevalence, improving healthcare infrastructure, increasing disposable incomes, and growing government initiatives to improve cancer care. Key players such as Exact Sciences, Hologic, Genomic Health, Cancer Genetics, Qiagen, NantHealth, Thermo Fisher Scientific, Illumina, Myriad Genetics, and F. Hoffmann-La Roche are actively engaged in strategic initiatives. These strategies include mergers and acquisitions to expand their product portfolios and geographical reach, collaborations with research institutions and pharmaceutical companies for new biomarker discovery and test development, and continuous investment in R&D to launch innovative and more sensitive diagnostic solutions. Their focus on improving test accuracy, reducing turnaround times, and increasing accessibility remains central to maintaining their competitive edge in this dynamic market.

Quick Stats

  • Market Size (2025):

    USD 16.8 Billion

  • Projected Market Size (2035):

    USD 52.2 Billion

  • Leading Segment:

    Polymerase Chain Reaction (38.5% Share)

  • Dominant Region (2025):

    North America (41.2% Share)

  • CAGR (2026-2035):

    11.4%

Global Oncology Molecular Diagnostic Market Emerging Trends and Insights

Liquid Biopsy Expanding Precision Oncology

Liquid biopsy is revolutionizing precision oncology by enabling noninvasive cancer detection and characterization. This advanced technology analyzes tumor derived material, like circulating tumor DNA, from blood samples. Its expansion is driven by unparalleled advantages in monitoring treatment response and detecting residual disease post surgery, often before clinical recurrence.

Early cancer detection via liquid biopsy offers promise for improved patient outcomes, especially in screening high risk individuals. It facilitates real time tracking of tumor evolution, identifying resistance mechanisms and guiding subsequent therapeutic decisions. This dynamic approach allows for personalized treatment adjustments based on a patient's evolving cancer, moving beyond static tissue biopsies. The technology is also proving invaluable for minimal residual disease detection, guiding adjuvant therapy decisions and improving disease surveillance. Liquid biopsy's adaptability across various cancer types underscores its growing importance in tailoring oncology care.

AI Driven Companion Diagnostics Evolution

AI driven companion diagnostics are revolutionizing oncology by enhancing precision medicine. This trend signifies a shift from traditional diagnostics to intelligent systems that analyze vast molecular data. AI algorithms meticulously correlate genetic mutations, protein expression, and tumor characteristics with drug responses. This enables oncologists to select the most effective targeted therapies for individual cancer patients, minimizing trial and error. The evolution involves sophisticated machine learning models predicting patient outcomes and identifying individuals most likely to benefit from specific treatments. This proactive approach optimizes therapeutic strategies, reduces adverse events, and improves patient quality of life. The integration of AI accelerates biomarker discovery and validation, leading to faster development of new companion diagnostic tests and propelling personalized cancer care forward.

Multiomics Platforms Revolutionizing Cancer Profiling

Multiomics platforms are profoundly transforming cancer profiling by integrating diverse molecular data streams. These platforms meticulously analyze genomic, transcriptomic, proteomic, and metabolomic information from a single patient sample. This comprehensive approach provides an unprecedentedly holistic view of the tumor microenvironment, encompassing its molecular landscape, cellular interactions, and metabolic vulnerabilities. By moving beyond single analyte analysis, multiomics unveils complex biological networks driving cancer progression and drug resistance. This integrated data empowers researchers and clinicians to develop more precise diagnostic and prognostic biomarkers, identify novel therapeutic targets, and ultimately personalize cancer treatment strategies with greater accuracy and efficacy, predicting patient responses and monitoring disease recurrence.

What are the Key Drivers Shaping the Global Oncology Molecular Diagnostic Market

Advancements in Precision Medicine & Biomarker Discovery

The ongoing revolution in precision medicine is a primary force propelling the global oncology molecular diagnostic market. As scientific understanding of cancer biology deepens, there is an escalating demand for diagnostics that can identify specific genetic alterations, protein expressions, and other molecular markers unique to an individual's tumor. This allows for targeted therapies that are more effective and have fewer side effects than traditional chemotherapy. Biomarker discovery, driven by genomics, proteomics, and epigenomics research, continually unveils new molecular targets. These discoveries directly translate into the development of novel companion diagnostics and theranostics, essential for selecting patients most likely to respond to specific treatments, monitoring treatment efficacy, and detecting minimal residual disease. This continuous innovation in identifying and leveraging actionable biomarkers fuels the expansion of the molecular diagnostics landscape in oncology.

Expanding Adoption of Companion Diagnostics & Targeted Therapies

The increasing integration of companion diagnostics with targeted therapies is a significant driver in the global oncology molecular diagnostic market. As our understanding of cancer at a molecular level grows, so does the development of highly specific drugs designed to target particular genetic mutations or protein expressions within tumors. Companion diagnostics are essential tools that identify which patients are most likely to benefit from these precise therapies, predicting treatment response and guiding clinical decisions. This symbiotic relationship ensures patients receive the most effective and least toxic treatments, moving away from a one size fits all approach. The expanding approval of new targeted therapies, each requiring a corresponding diagnostic test, fuels the demand for advanced molecular diagnostic solutions across various cancer types, consequently propelling market growth.

Increasing Incidence of Cancer & Demand for Early Detection

The escalating global incidence of various cancer types is a primary driver fueling the oncology molecular diagnostic market. As more individuals receive cancer diagnoses, there is a corresponding surge in the demand for accurate and timely detection methods. Early detection is critical for improving patient outcomes, enabling prompt treatment initiation and personalized therapeutic strategies. Molecular diagnostics offer unparalleled precision in identifying specific biomarkers, genetic mutations, and gene expression profiles associated with different cancers, often before clinical symptoms appear. This capability allows for risk stratification, disease monitoring, and guiding treatment selection. The increasing awareness among healthcare providers and patients regarding the benefits of early and precise cancer identification further propels the adoption of these advanced diagnostic tools.

Global Oncology Molecular Diagnostic Market Restraints

High Costs of Advanced Molecular Diagnostics and Reimbursement Challenges

The substantial expense associated with cutting edge molecular diagnostics poses a significant hurdle for widespread adoption in global oncology. These advanced tests, crucial for personalized cancer treatment, involve costly technologies and specialized personnel. Consequently, healthcare systems and individual patients often struggle to afford them, particularly in resource constrained regions. Furthermore, inconsistent and often inadequate reimbursement policies from insurance providers further exacerbate the problem. Many innovative diagnostic tests lack clear coding and coverage guidelines, leading to denials or partial payments that do not cover the true cost. This creates financial barriers for both providers offering these tests and patients who could benefit from them, effectively limiting market penetration and accessibility despite the clear clinical advantages.

Regulatory Hurdles and Lengthy Approval Processes for Novel Companion Diagnostics

Regulatory hurdles significantly impede the swift adoption of novel companion diagnostics in the global oncology molecular diagnostic market. Developing these sophisticated tools requires extensive clinical validation to demonstrate their accuracy and clinical utility in identifying patients most likely to benefit from specific cancer therapies. Before reaching patients, these diagnostics must navigate rigorous approval processes set by regulatory bodies worldwide. This often involves lengthy premarket reviews, extensive documentation, and multiple rounds of submission and feedback. The protracted timelines associated with these regulatory pathways translate into delayed market entry for innovative products, restricting access for both clinicians and patients to advanced diagnostic solutions that could significantly improve cancer treatment outcomes. This prolonged process not only increases development costs but also slows down the integration of precision medicine into routine oncology practice.

Global Oncology Molecular Diagnostic Market Opportunities

Expanding Clinical Adoption of Liquid Biopsy for Early Cancer Detection and MRD Monitoring

The significant opportunity involves accelerating the widespread integration of liquid biopsy into routine clinical oncology. This advanced non-invasive blood test offers a paradigm shift in cancer management. For early cancer detection, it provides unprecedented potential to identify malignancies at their most treatable stages, dramatically improving patient prognoses. Simultaneously, liquid biopsy is critical for precise Minimal Residual Disease MRD monitoring post treatment, enabling early detection of recurrence and guiding timely therapeutic adjustments. As healthcare systems globally prioritize precision medicine, especially in high growth regions like Asia Pacific, the demand for more accessible and accurate diagnostic tools is surging. Expanding clinical adoption necessitates robust validation, increased awareness among clinicians, and established reimbursement pathways. This growth ensures enhanced diagnostic efficiency, personalized treatment strategies, and ultimately, improved long term survival rates for cancer patients worldwide.

Driving Precision Oncology Through Advanced Biomarker Discovery and Companion Diagnostics for Novel Therapies

The global oncology molecular diagnostic market presents a transformative opportunity by driving precision oncology through advanced biomarker discovery. As novel targeted therapies and immunotherapies proliferate, there is an escalating demand for sophisticated diagnostic tools. The core opportunity lies in identifying new, clinically actionable biomarkers that predict patient response or resistance to these innovative treatments. This directly fuels the development and commercialization of companion diagnostics, which are crucial for guiding therapeutic decisions and ensuring optimal patient selection. Companies excelling in advanced biomarker research and assay development can position themselves as indispensable partners for pharmaceutical firms launching new drugs. This integration of diagnostics with drug development enhances therapeutic efficacy, minimizes adverse events, and ultimately improves patient outcomes globally. The market rewards innovation in highly sensitive and specific diagnostic platforms that facilitate personalized cancer care, creating significant growth potential for providers of these essential molecular tests. This paradigm shift makes precise patient stratification a cornerstone of modern cancer treatment.

Global Oncology Molecular Diagnostic Market Segmentation Analysis

Key Market Segments

By Test Type

  • •Polymerase Chain Reaction
  • •Next Generation Sequencing
  • •In Situ Hybridization
  • •Mass Spectrometry
  • •Fluorescent In Situ Hybridization

By Application

  • •Breast Cancer
  • •Lung Cancer
  • •Colorectal Cancer
  • •Prostate Cancer
  • •Hematological Malignancies

By End Use

  • •Hospitals
  • •Diagnostic Laboratories
  • •Research Institutions
  • •Homecare

By Sample Type

  • •Blood
  • •Tissue
  • •Bone Marrow
  • •Urine
  • •Saliva

Segment Share By Test Type

Share, By Test Type, 2025 (%)

  • Polymerase Chain Reaction
  • Next Generation Sequencing
  • Fluorescent In Situ Hybridization
  • In Situ Hybridization
  • Mass Spectrometry
maklogo
$16.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Polymerase Chain Reaction dominating the Global Oncology Molecular Diagnostic Market?

Polymerase Chain Reaction PCR leads the market due to its established reliability, cost effectiveness, and widespread adoption in various cancer diagnostics. Its high sensitivity and specificity for detecting genetic mutations and gene expression profiles make it indispensable for rapid and accurate disease identification and monitoring in oncology settings. This foundational technology is easily accessible and forms the backbone of many molecular diagnostic workflows in hospitals and diagnostic laboratories globally, securing its substantial market share.

How do different cancer applications influence molecular diagnostic market segmentation?

The market is significantly shaped by application segments like Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Hematological Malignancies. Each cancer type necessitates specific diagnostic panels and molecular targets, driving demand for particular test types such as Next Generation Sequencing for comprehensive genomic profiling in lung cancer or targeted PCR assays for common breast cancer mutations. This application specific demand dictates the adoption rates of various technologies and their penetration into different end use settings.

What role do sample types play in the evolution of oncology molecular diagnostics?

Sample types like Blood, Tissue, Bone Marrow, Urine, and Saliva are critical determinants of test type adoption and market accessibility. While tissue biopsies remain the gold standard, the growing preference for minimally invasive liquid biopsies using blood or urine is propelling the development and utilization of highly sensitive technologies like Next Generation Sequencing and advanced PCR assays. This shift towards non invasive methods significantly influences diagnostic workflows in both hospitals and homecare settings, broadening patient access and convenience for cancer detection and monitoring.

Global Oncology Molecular Diagnostic Market Regulatory and Policy Environment Analysis

The global oncology molecular diagnostic market operates within a complex and fragmented regulatory landscape. Key regulatory bodies such as the US Food and Drug Administration FDA, European Medicines Agency EMA, China’s National Medical Products Administration NMPA, and Japan’s Pharmaceuticals and Medical Devices Agency PMDA each maintain distinct approval pathways for in vitro diagnostics and companion diagnostics. Rigorous validation and clinical evidence are mandatory, impacting product development timelines and costs.

Reimbursement policies are crucial for market adoption, varying significantly across national healthcare systems and often lagging behind technological advancements. Data privacy regulations, including GDPR in Europe and HIPAA in the US, profoundly influence data collection, storage, and sharing practices for genetic information. Policies increasingly promote personalized medicine and precision oncology initiatives, fostering innovation while demanding stringent quality control and accreditation standards for diagnostic laboratories. Harmonization efforts aim to streamline international approvals, yet significant regional disparities persist, creating barriers to market entry and broad patient access. Ethical considerations regarding equitable access and informed consent are also integral to policy development.

Which Emerging Technologies Are Driving New Trends in the Market?

The global oncology molecular diagnostic market is experiencing significant expansion driven by revolutionary innovations. Liquid biopsies, particularly those leveraging circulating tumor DNA, are transforming early detection, treatment monitoring, and minimal residual disease assessment, offering less invasive and more frequent testing capabilities. Next Generation Sequencing continues its evolution, enabling comprehensive genomic profiling and the identification of an expanding array of actionable biomarkers, crucial for precision oncology.

Emerging technologies like spatial transcriptomics provide unprecedented insights into tumor microenvironments, while advanced bioinformatics coupled with artificial intelligence and machine learning enhances biomarker discovery and diagnostic accuracy. Multiplexing technologies are enabling simultaneous detection of multiple analytes, increasing efficiency and diagnostic power. The integration of point of care solutions promises faster results and broader accessibility. These advancements are collectively enhancing diagnostic precision, guiding targeted therapies, and improving patient outcomes, fueling substantial market progression.

Global Oncology Molecular Diagnostic Market Regional Analysis

Global Oncology Molecular Diagnostic Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
41.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 41.2% share

North America stands as the dominant region in the Global Oncology Molecular Diagnostic Market, commanding a substantial 41.2% market share. This leadership is driven by several key factors. The region boasts highly developed healthcare infrastructure and significant investment in research and development. There is a strong presence of major pharmaceutical and biotechnology companies, actively innovating in molecular diagnostics. High awareness among healthcare professionals and patients regarding personalized medicine and early cancer detection also contributes to its market prominence. Favorable reimbursement policies for advanced diagnostic tests further stimulate adoption. Moreover, a high prevalence of various cancer types coupled with an aging population fuels demand for precise and effective diagnostic tools in the region.

Fastest Growing Region

Asia Pacific · 11.2% CAGR

Asia Pacific is poised for significant expansion in the Global Oncology Molecular Diagnostic Market, projected to be the fastest growing region with an impressive CAGR of 11.2% from 2026 to 2035. This rapid growth is fueled by several key factors. A rising prevalence of cancer cases across the region coupled with increasing healthcare expenditure significantly drives demand for advanced diagnostic tools. Furthermore greater awareness about personalized medicine and early disease detection among both patients and healthcare professionals is accelerating adoption. Government initiatives supporting cancer research and diagnostics coupled with improving access to advanced medical technologies further bolster market expansion. The expanding elderly population also contributes to the heightened need for effective oncology molecular diagnostics making Asia Pacific a pivotal growth hub.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical stability and trade relations are crucial. Disruptions in global supply chains, due to conflicts or protectionist policies, can impact the availability and cost of reagents and specialized equipment for oncology molecular diagnostics. Regulatory harmonization or divergence across major economies also plays a significant role. Geopolitical alliances and rivalries influence research collaborations and technology transfer, potentially accelerating or hindering market development. Furthermore, national healthcare priorities, often influenced by political agendas, dictate funding for innovative diagnostic technologies.

Macroeconomic factors significantly shape the market. Economic growth and healthcare expenditure directly correlate with adoption rates, particularly for advanced, often expensive, molecular tests. Inflationary pressures can increase operational costs for manufacturers and service providers, potentially raising prices for end users. Fluctuations in currency exchange rates impact profitability for multinational companies and can influence pricing strategies. Investment in research and development, driven by economic prosperity and government grants, is vital for bringing novel diagnostic solutions to market.

Recent Developments

  • March 2025

    Exact Sciences announced a strategic partnership with NantHealth to integrate their advanced genomic profiling tests into NantHealth's comprehensive oncology decision support platform. This collaboration aims to provide oncologists with streamlined access to actionable molecular insights for personalized treatment planning.

  • July 2024

    Thermo Fisher Scientific launched a new liquid biopsy panel for early-stage lung cancer detection and recurrence monitoring. This product utilizes highly sensitive next-generation sequencing to identify circulating tumor DNA with improved specificity and turnaround time.

  • November 2024

    Illumina acquired a significant stake in Cancer Genetics, aiming to bolster its portfolio in oncology diagnostics and accelerate the development of companion diagnostics for novel cancer therapies. This acquisition combines Illumina's sequencing prowess with Cancer Genetics' expertise in cancer-specific genetic testing.

  • February 2025

    Myriad Genetics expanded its strategic initiative to establish a global network of accredited laboratories for its hereditary cancer testing services. This move aims to increase accessibility to essential genetic testing in underserved regions and support early cancer risk assessment worldwide.

Key Players Analysis

Key players like Exact Sciences and Myriad Genetics are crucial, driving market growth through innovative technologies like NGS and PCR. Thermo Fisher Scientific and Illumina dominate with their comprehensive platforms. Roche and Hologic leverage their global presence and strategic partnerships, while Cancer Genetics and Genomic Health focus on specialized diagnostic solutions. These companies employ various strategic initiatives, including R&D, acquisitions, and collaborations, to expand their market share and address the rising demand for personalized oncology treatments.

List of Key Companies:

  1. Exact Sciences
  2. Hologic
  3. Genomic Health
  4. Cancer Genetics
  5. Qiagen
  6. NantHealth
  7. Thermo Fisher Scientific
  8. Illumina
  9. Myriad Genetics
  10. F. HoffmannLa Roche
  11. PerkinElmer
  12. Agilent Technologies
  13. BioMrieux
  14. Abbott Laboratories
  15. Roche
  16. Danaher Corporation

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 16.8 Billion
Forecast Value (2035)USD 52.2 Billion
CAGR (2026-2035)11.4%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Test Type:
    • •Polymerase Chain Reaction
    • •Next Generation Sequencing
    • •In Situ Hybridization
    • •Mass Spectrometry
    • •Fluorescent In Situ Hybridization
  • By Application:
    • •Breast Cancer
    • •Lung Cancer
    • •Colorectal Cancer
    • •Prostate Cancer
    • •Hematological Malignancies
  • By End Use:
    • •Hospitals
    • •Diagnostic Laboratories
    • •Research Institutions
    • •Homecare
  • By Sample Type:
    • •Blood
    • •Tissue
    • •Bone Marrow
    • •Urine
    • •Saliva
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Oncology Molecular Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
5.1.1. Polymerase Chain Reaction
5.1.2. Next Generation Sequencing
5.1.3. In Situ Hybridization
5.1.4. Mass Spectrometry
5.1.5. Fluorescent In Situ Hybridization
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.2.1. Breast Cancer
5.2.2. Lung Cancer
5.2.3. Colorectal Cancer
5.2.4. Prostate Cancer
5.2.5. Hematological Malignancies
5.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.3.1. Hospitals
5.3.2. Diagnostic Laboratories
5.3.3. Research Institutions
5.3.4. Homecare
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Sample Type
5.4.1. Blood
5.4.2. Tissue
5.4.3. Bone Marrow
5.4.4. Urine
5.4.5. Saliva
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Oncology Molecular Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
6.1.1. Polymerase Chain Reaction
6.1.2. Next Generation Sequencing
6.1.3. In Situ Hybridization
6.1.4. Mass Spectrometry
6.1.5. Fluorescent In Situ Hybridization
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Colorectal Cancer
6.2.4. Prostate Cancer
6.2.5. Hematological Malignancies
6.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.3.1. Hospitals
6.3.2. Diagnostic Laboratories
6.3.3. Research Institutions
6.3.4. Homecare
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Sample Type
6.4.1. Blood
6.4.2. Tissue
6.4.3. Bone Marrow
6.4.4. Urine
6.4.5. Saliva
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Oncology Molecular Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
7.1.1. Polymerase Chain Reaction
7.1.2. Next Generation Sequencing
7.1.3. In Situ Hybridization
7.1.4. Mass Spectrometry
7.1.5. Fluorescent In Situ Hybridization
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Hematological Malignancies
7.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.3.3. Research Institutions
7.3.4. Homecare
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Sample Type
7.4.1. Blood
7.4.2. Tissue
7.4.3. Bone Marrow
7.4.4. Urine
7.4.5. Saliva
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Oncology Molecular Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
8.1.1. Polymerase Chain Reaction
8.1.2. Next Generation Sequencing
8.1.3. In Situ Hybridization
8.1.4. Mass Spectrometry
8.1.5. Fluorescent In Situ Hybridization
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Colorectal Cancer
8.2.4. Prostate Cancer
8.2.5. Hematological Malignancies
8.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Research Institutions
8.3.4. Homecare
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Sample Type
8.4.1. Blood
8.4.2. Tissue
8.4.3. Bone Marrow
8.4.4. Urine
8.4.5. Saliva
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Oncology Molecular Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
9.1.1. Polymerase Chain Reaction
9.1.2. Next Generation Sequencing
9.1.3. In Situ Hybridization
9.1.4. Mass Spectrometry
9.1.5. Fluorescent In Situ Hybridization
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Colorectal Cancer
9.2.4. Prostate Cancer
9.2.5. Hematological Malignancies
9.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Research Institutions
9.3.4. Homecare
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Sample Type
9.4.1. Blood
9.4.2. Tissue
9.4.3. Bone Marrow
9.4.4. Urine
9.4.5. Saliva
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Oncology Molecular Diagnostic Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Test Type
10.1.1. Polymerase Chain Reaction
10.1.2. Next Generation Sequencing
10.1.3. In Situ Hybridization
10.1.4. Mass Spectrometry
10.1.5. Fluorescent In Situ Hybridization
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Colorectal Cancer
10.2.4. Prostate Cancer
10.2.5. Hematological Malignancies
10.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.3.1. Hospitals
10.3.2. Diagnostic Laboratories
10.3.3. Research Institutions
10.3.4. Homecare
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Sample Type
10.4.1. Blood
10.4.2. Tissue
10.4.3. Bone Marrow
10.4.4. Urine
10.4.5. Saliva
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Exact Sciences
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Hologic
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Genomic Health
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Cancer Genetics
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Qiagen
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. NantHealth
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Thermo Fisher Scientific
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. Illumina
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Myriad Genetics
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. F. HoffmannLa Roche
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. PerkinElmer
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Agilent Technologies
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. BioMrieux
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Abbott Laboratories
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Roche
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis
11.2.16. Danaher Corporation
11.2.16.1. Business Overview
11.2.16.2. Products Offering
11.2.16.3. Financial Insights (Based on Availability)
11.2.16.4. Company Market Share Analysis
11.2.16.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.16.6. Strategy
11.2.16.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 2: Global Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 3: Global Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 4: Global Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Sample Type, 2020-2035

Table 5: Global Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 7: North America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 8: North America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 9: North America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Sample Type, 2020-2035

Table 10: North America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 12: Europe Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 13: Europe Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 14: Europe Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Sample Type, 2020-2035

Table 15: Europe Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 17: Asia Pacific Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 18: Asia Pacific Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 19: Asia Pacific Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Sample Type, 2020-2035

Table 20: Asia Pacific Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 22: Latin America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 23: Latin America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 24: Latin America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Sample Type, 2020-2035

Table 25: Latin America Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Test Type, 2020-2035

Table 27: Middle East & Africa Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 28: Middle East & Africa Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 29: Middle East & Africa Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Sample Type, 2020-2035

Table 30: Middle East & Africa Oncology Molecular Diagnostic Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;